Fatima Bosch – The Scientist Behind – Gene Therapy

Who is Fatima Bosch?

Fatima Bosch i Tubert is a Spanish biochemist and pharmacist, best known for her pioneering work in gene therapy for metabolic diseases.

• She is a Full Professor of Biochemistry and Molecular Biology at the Universitat Autònoma de Barcelona (UAB).
• She directs the Centre for Animal Biotechnology and Gene Therapy (CBATEG) at UAB.
• She has authored well over 300 scientific publications and has been deeply involved in European and Spanish gene therapy societies, including helping found the European Society of Gene and Cell Therapy and leading the Spanish Society of Gene and Cell Therapy.

In short: when you see headlines about gene therapy “curing” diabetes or obesity in animals, there’s a good chance Bosch’s team is somewhere in the story.

Why is Fatima Bosch in the news again?

Her name has resurfaced in science and health news for two main reasons:

1. Metabolic disease gene therapy successes (especially in mice and dogs).
2. A new one-shot gene therapy approach for a serious liver disease called MASH (Metabolic dysfunction-associated steatohepatitis).

These developments make her work a key reference point in the global push to use gene therapy beyond rare genetic diseases and into common conditions like type 2 diabetes, obesity and fatty liver disease.

Breakthroughs in diabetes and obesity: from mice to dogs

Bosch’s group has published a series of landmark studies over the last decade:

1. Curing type 2 diabetes and obesity in mice

In 2018, UAB announced that her team had “cured” obesity and type 2 diabetes in mice using a single gene therapy injection:

• They used an adeno-associated virus (AAV) vector to deliver the gene for FGF21 (Fibroblast Growth Factor 21) to organs like the liver or muscle.
• After one treatment, the mice:
  • Lost excess body weight
  • Improved insulin sensitivity
  • Normalised blood sugar
  • Showed no long-term adverse effects in the study window

This work suggested that a one-time gene therapy could replace daily drugs for some metabolic disorders in the future.

2. Long-term diabetes control in dogs

Earlier, Bosch’s team and collaborators showed that gene therapy can control type 1 diabetes in dogs, which are large animals physiologically closer to humans than mice

• Dogs received a single injection of genes for insulin and glucokinase into skeletal muscle.
• The treatment kept blood sugar in a healthy range for years, avoiding dangerous highs and lows.
• An eight-year follow-up confirmed long-term efficacy and safety, making it a rare and powerful proof-of-concept in a large animal model.

These results are widely cited because they show gene therapy can work beyond rare inherited disorders and might one day be applied to common diseases like diabetes.

New headline: Gene therapy for MASH liver disease

More recently (2024), UAB highlighted another Bosch-led project: a single-dose gene therapy that cured MASH (a severe form of fatty liver disease) in animal models.

• MASH (Metabolic dysfunction-associated steatohepatitis) can progress to cirrhosis and liver cancer.
• Her team used an AAV vector to deliver a therapeutic gene that:
  • Reduced liver fat
  • Resolved inflammation and fibrosis
  • Improved overall liver function

Bosch described the strategy as a potential “major advance” not just for MASH but also for other metabolic diseases that affect millions worldwide.

This is part of why she’s being discussed so much again: the research fits perfectly into the global effort to tackle obesity-linked liver disease with more durable solutions.

How does her work change the way we think about treatment?

Bosch’s research pushes a very specific idea:

Instead of taking pills every day, could we treat certain chronic diseases once with gene therapy and get long-term benefit?

Her lab’s studies suggest that, at least in animals:

• One-time treatment can normalise blood sugar and body weight in diabetes and obesity models.
• Long-term follow-up in dogs shows years of stable glucose control without repeated injections.
• A similar single-shot approach may tackle complex liver disease like MASH.

We’re not yet at routine human use, but her work gives regulators, companies and other researchers hard data that such treatments can be safe and effective over long periods in large animals.

Challenges and next steps

Even with all the exciting data, several hurdles remain before Bosch’s approaches can become everyday medicine:

• Safety in humans: Long-term safety of viral vectors and high, sustained levels of therapeutic proteins need careful monitoring in clinical trials.
• Cost and access: Gene therapies are currently extremely expensive. Scaling them for common diseases (like diabetes) will demand new pricing and manufacturing models.
• Regulation and ethics: Because these therapies can last many years, regulators require very strong evidence and long-term follow-up.
• Translation from animals to people: Not all results in mice or dogs translate directly. Human trials will determine how far these successes can go.

Still, the direction of travel is clear: Bosch’s body of work is one of the reasons gene therapy is now discussed not just for rare, inherited disorders but as a possible tool against mainstream metabolic diseases.

FAQs on Fatima Bosch at a glance

Who is Fatima Bosch?
A Spanish biochemist and pharmacist, Full Professor at the Autonomous University of Barcelona, and Director of CBATEG, specialising in gene therapy for metabolic diseases.

What is she best known for?
For leading gene therapy studies that:

• Correct type 1 diabetes in dogs long-term
• Reverse obesity and type 2 diabetes in mice
• Offer promising one-shot treatments for liver disease (MASH).

Is her work already used in hospitals?
Not yet on a routine basis. Most of her breakthroughs are pre-clinical, meaning they are in animal models. They form the groundwork for future human trials.

Why is she trending now?
Because of recent announcements about using gene therapy to treat MASH and renewed interest in long-term diabetes and obesity gene-therapy approaches as potential game-changers in metabolic medicine.

---

Happening Now!

• Nigeria Travel Restrictions: What’s Really Going On and What Travelers Need to Know.
• Ukraine Claims Underwater Drone Attack on Russian Submarine in Black Sea Port
• Aisha Buhari Trends Online: Why Her Recent Comments Have Nigerians Talking
• Best Buy 2025: What’s New
• Bengals vs Ravens (2025) — Big Turnaround